GlassScriptPhysician profile
Bushra Javed
NPI 1629322987
$9,946.08
in general payments reported to CMS, 2019-2025
38 companies · $4,484 in 2025
The $4,484 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2021: $315 · 2022: $58.52 · 2023: $1,110 · 2024: $3,783 · 2025: $4,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,881 · Education: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,880.71 |
| Education | $495.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $1,424.60 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $1,367.66 | 2019-2025 | Ultomiris, Soliris |
| Celgene Corporation | $723.71 | 2023-2025 | Zeposia |
| Abbvie INC. | $701.69 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $547.49 | 2023-2025 | |
| Ucb, INC. | $469.84 | 2023-2025 | Briviact, Rystiggo, Nayzilam |
| Biogen, INC. | $425.94 | 2023-2025 | Tysabri, Vumerity, Leqembi |
| Mallinckrodt Hospital Products INC. | $417.45 | 2023-2025 | Acthar |
| Abbott Laboratories | $373.49 | 2021-2022 | |
| Lilly USA, LLC | $360.12 | 2023-2025 | Emgality, Amyvid, Kisunla |
| Amgen INC. | $314.21 | 2024-2025 | Uplizna |
| Argenx US, INC. | $295.56 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $271.00 | 2024-2025 | |
| Banner Life Sciences, LLC | $221.53 | 2023-2024 | |
| Csl Behring | $174.09 | 2023-2025 | Hizentra |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $172.76 | 2024-2025 | Gamunex-C |
| Genentech USA, INC. | $155.23 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Teva Pharmaceuticals USA, INC. | $150.22 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Ani Pharmaceuticals, INC. | $143.38 | 2023-2025 | Purified Cortrophin Gel |
| Neurelis, INC. | $137.99 | 2023-2025 | Valtoco |
| Ipsen Biopharmaceuticals, INC | $132.36 | 2024-2025 | Dysport |
| Genzyme Corporation | $131.17 | 2025 | |
| Pfizer INC. | $128.15 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $99.47 | 2024-2025 | Ponvory |
| Neurocrine Biosciences, INC. | $92.93 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $72.64 | 2024-2025 | Symbravo, Sunosi |
| Lundbeck LLC | $67.12 | 2023-2025 | Vyepti |
| Acorda Therapeutics, INC | $58.51 | 2023 | Ampyra |
| Sk Life Science, INC. | $51.36 | 2023 | |
| Eisai INC. | $47.15 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $42.24 | 2025 | Crexont |
| Merz Pharmaceuticals, LLC | $38.32 | 2025 | Ampyra, Xeomin, Inbrija |
| Sandoz INC. | $28.50 | 2025 | |
| Horizon Therapeutics Plc | $24.88 | 2023 | Uplizna |
| Ultragenyx Pharmaceutical INC. | $24.36 | 2024 | Dojolvi |
| Impel Pharmaceuticals INC. | $22.87 | 2023 | Trudhesa |
| Janssen Biotech, INC. | $19.36 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $16.73 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bushra Javed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.